The setting in which neonatal CHD is first recognised has an impact on preoperative condition, which in turn influences postoperative progress and survival after surgery. Optimal screening procedures and access to specialist care will improve outcome for neonates undergoing cardiac surgery.

This article reviews evidence for the involvement of cell-derived microparticles (MP) in transfusion-related adverse events. The controversy concerning possible added risk of older vs. fresher stored blood is also reviewed, and is consistent with the hypothesis that MP are involved with adverse events. Although all types of circulating MP are discussed, the emphasis is on red cell-derived MP (RMP). The evidence is particularly strong for involvement of RMP in transfusion-related acute lung injury (TRALI), but also for post-operative thrombosis. However, this evidence is largely circumstantial. Work in progress to directly test the hypothesis is also briefly reviewed.

Evaluation of TTFM is valuable in determining the status of a coronary graft after CABG. Correct interpretation of flow patterns allows for correction of abnormalities prior to chest closure.

No abstract